Vaccine XH001 plus chemo after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new tumor vaccine (XH001) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to lower the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had surgery to remove your pancreatic cancer, and the surgeon removed all visible tumor (clear or nearly clear margins).
- You should not have received any chemotherapy or radiation before surgery.
- You must be in generally good health (able to perform daily activities without help).
- If you could become pregnant, you must have a negative pregnancy test and use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.